Human proteomics: from the operating room to the lab and back
Human proteomics: from the operating room to the lab and back
Optimizing platforms for surgical specimen collection and deep human phenotyping was used to enhance protein biomarker identification using proteomic tools. A series of studies using human eye fluids has helped to diagnose inflammatory retinal disease, select personalized therapies, stage cancer, and point to new therapeutic strategies. These approaches can be broadly applied to human surgical disease.
Learning Objectives
- Learn workflow for human surgical specimen collection
- Learn human disease proteomics experimental design
- Learn future applications of human proteomics to disease diagnosis and treatment
Vinit Mahajan, MD, PhD
Vice Chair for Research, Director, Omics Lab, Molecular Surgery Program
Stanford University
Dr. Mahajan is a vitreoretinal surgeon and professor in the Department of Ophthalmology at Stanford University. He is the Vice Chair for Research and directs the Molecular Surgery Program and the NIH-funded Omics Laboratory that uses high-throughput methods in proteomics, genomics, and phenomics to identify molecules involved in eye disease. His research team discovered the first gene to cause non-syndromic uveitis and is now using protein crystallography to design therapeutic inhibitors for calpain-5. Mahajan and his team performed the first CRISPR gene editing therapy for eye disease in human stem cells. Using translational proteomics, Mahajan’s multidisciplinary team is developing new precision health approaches using molecular biomarkers to diagnose retinal disease, select personalized therapies, and decode the anatomic structures of the human eye.
Human proteomics: from the operating room to the lab and back
A presentation by Vinit Mahajan, MD, PhD
More webinars
WebinarMillions for Proteomics Research in the Peer Reviewed Medical Research Program
How SomaLogic Technologies can give your research programs an edge
WebinarA proteomics signature of NASH
There is a high unmet need for non-invasive tests that can robustly and reliably assess NAFLD for diagnosis, prognosis, and monitoring purposes. Large-scale profiling of serum/plasma proteins (proteomics) increasingly demonstrates utility to identify changes that accurately reflect and predict disease states and outcomes, including the fibrosis component of NASH that is driven by disease activity and remains the most robust histological marker of prognosis.
WebinarEarly Detection, Risk Stratification, and Drug Target Identification in Pulmonary Arterial Hypertension with Plasma Proteomics
Pulmonary arterial hypertension is a rare condition that is clinically heterogenous and often diagnosed late in disease progression. Plasma proteomics offers the potential to diagnose earlier, risk-stratify patients, and identify new drug targets.